THE COMPLEX OF INFORMATIVE IMMUNOLOGICAL PARAMETERS FOR BREAST CANCER OUTCOME PROGNOSIS
https://doi.org/10.20538/1682-0363-2015-3-30-34
Abstract
Prognosis of disease outcome is important procedure for cancer patients treatment. The article presents the problem of elicitation of breast cancer prognosis criteria from immunological data as parameters complex.
The aim is to identify necessary and sufficient amount of immunological parameters for accurate classification of breast cancer patients with various outcomes – clinical remission and hematogenous metastases.
Material and methods. 36 immunological parameters were studied in 197 breast cancer patients T1–4N0–3M0. The “next neighbor” algorithm was used for identification of informative parameters. Detection of informative parameters complex was carried out by using ADD and DEL methods.
Results. Two sets of informative immunological parameters were detected. The ADD method elicited parameters related to T-cell immunity, DEL – to humoral response.
Conclusions. The complex of 17–19 immunological parameters characterizing different elements of immune system is necessary for accurate classification of breast cancer patients with different outcomes (presence/absence of hematogenous metastases).
About the Authors
M. N. Stakheyeva
Tomsk Саnсеr Rеsеаrсh lnstitute, Tomsk
Russian Federation
Stakheyeva Marina N.
Russian Federation
Stakheyeva Marina N.
A. P. Serykh
National Research Tomsk State University, Tomsk
Russian Federation
Russian Federation
S. I. Karas
Siberian State Medical University, Tomsk
Russian Federation
Karas Sergey I.
Russian Federation
Karas Sergey I.
E. A. Perina
Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
References
1. Bozhok A.A., Semiglazov V.F., Semiglazov V.V. et al. Prognosis and predictive factors in breast cancer. Voprosy oncologii – Problems in Oncology, 2005, no. 51 (4), pp. 434–443 (in Russian).
2. Bozhenko V.K., Rozhkova N.I, Kudinova Ye.A., Trotsenko I.D. Gene expression profile as prognosis factor in breast cancer. Vestnik of RNCPP MH RF, 2011, no. 4 (11). URL: http://vestnik.rncrr.ru/vestnik–/v11/papers/bozh2_v11.htm (in Russian).
3. Heuvers M.E., Aerts J.G., Cornelissen R. et al. Patienttailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer, 2012, vol. 12, p. 580. doi: 10.1186/1471-2407-12-580.
4. Glants S. Medico-biological statistics. Moscow, Practics Publ., 1998. 459 p. (in Russian).
5. Fukunaga K. Introdution in statistical theory of images recognition. Moscow, Science Publ., 1979. 386 p. (in Russian).
6. Stakheyeva M.N., Eidenzon D.V., Slonimskaya E.M. et al. The interrelatinship between the immune system state as integrated unity and breast cancer clinical course. Sibirskiy onkologicheskiy zhurnal – Siberian Journal of Oncology, 2011, (2), pp. 11–19 (in Russian).
7. Galon J., Pages F., Marincola F.M. et al. The Immune Scoreas a New Possible Approach for the Classification of Cancer. Journal of Translational Medicine, 2012, 10, 1. doi: 10.1186/1479-5876-10-1.
8. Matsueda S. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases. Developmental and Comparative Immunology, 2013, 41 (1), pp. 68–76.
9. Muenst S., Soysal S.D., Gao F. et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat., 2013, 139 (3), pp. 667–676. doi: 10.1007/s10549-013-2581-3.
10. Pichler M., Hutterer G.C., Stoeckigt C. et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br. J. Cancer, 2013, 108 (4), pp. 901–907. doi: 10.1038/bjc.
11. Fox B.A., Schendel D.J., Butterfield L.H. et al. Defining the Critical Hurdles in Cancer Immunotherapy. Journal of Translational Medicine, 2011, 9, p. 214. doi: 10.1186/14795876-9-214.
12. Whiteside T.L. Immune Responses to Cancer: Are They Potential Biomarkers of Prognosis? Front Oncol., 2013, vol. 3, p. 107. doi: 10.3389/fonc.2013.00107.
13. McCoy M.J., Nowak A.K., van der Most R.G. Peripheral CD8+T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunology, Immunotherapy, 2013, 62 (3), pp. 29–39. doi: 10.1007/s00262-012-1360-z.
14. Swann J.B., Smyth M.J. Immune surveillance of tumors. The Journal of Clinical Investigation, 2007, 117 (5), pp. 1137–1146.
15. Lippitz B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol, 2013, 14 (6), pp. 218–228. doi: 10.1016/S1470-2045(12)70582-X.
Review
For citations:
Stakheyeva M.N., Serykh A.P., Karas S.I., Perina E.A. THE COMPLEX OF INFORMATIVE IMMUNOLOGICAL PARAMETERS FOR BREAST CANCER OUTCOME PROGNOSIS. Bulletin of Siberian Medicine. 2015;14(3):30-34. (In Russ.) https://doi.org/10.20538/1682-0363-2015-3-30-34
Views:
762
Email this article 